Navigation Links
Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST
Date:3/4/2009

EATONTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the fourth quarter and full year ended December 31, 2008.

"The last twelve months were an important transitional time for Osteotech. Our entire team worked diligently to execute our corporate strategy to leverage the Company's proprietary technology portfolio into unique, procedure-driven products providing a stable platform to support long-term sales growth and profitability," said Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech. "We continued to receive U.S. Food and Drug Administration (FDA) clearances for new products and our 2009 plan includes the launch of our MagniFuse(TM) Bone Graft and Plexur M(TM) Biocomposite, the re-launch of the Plexur P(R) platform and the unveiling of our first product based upon our proprietary human collagen technology platform, the DuraTech(TM) BioRegeneration Matrix. Complementing our progress within product development, we have also continued to execute our strategy to streamline and strengthen our access-based agency sales model. We remain encouraged by the progress we are making in these strategies and believe that once these initiatives are fully executed we will be well positioned to emerge as a leader in regenerative and biologic healing."

Recent and 2008 Corporate Developments

Product Development and Regulatory

  • In February 2009, the Company announced that it received 13485:2003 ISO certification indicating that its facilities meet the international standards for medical device manufacturing.
  • In December 2008, Osteotech initiated a pivotal clinical trial for its DuraTech BioRegeneration Matrix.
    '/>"/>

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Osteotech Announces Stock Repurchase Program
2. Osteotechs Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio
3. Osteotech Reports 2008 Third Quarter Financial Results
4. Osteotech Receives FDA Clearance for its Next Generation Grafting Material
5. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
6. Cato T. Laurencin, M.D., Ph.D. to Join Osteotech Board of Directors
7. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
8. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
9. Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10%
10. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
11. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... -- Ambit Biosciences Corporation announced today the enrollment and ... Cancer Center of the first patient in the ACE ... fficacy) Phase 2 pivotal trial in patients with ... is a novel, orally available, potent and highly selective ... tyrosine kinase-3 (FLT3) inhibitor. The ACE study is ...
(Date:12/11/2009)... Gwathmey, Inc., a pre-clinical contract research ... aureus, and cardiovascular disease announces a new CEO. ... Rosalie Dunn, Ph.D., has joined Gwathmey as Chief ... years of experience working with small businesses and ... Dr. Dunn managed multimillion dollar portfolios for the ...
(Date:12/10/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced today ... 15,000,000 shares of its common stock at a price ... also granted to the underwriters a 30-day option to ... stock to cover overallotments, if any. The offering ... to customary closing conditions. ,, J. P. Morgan Securities ...
(Date:12/10/2009)... National Institutes of Health (NIH), awarded a $2.18 million grant ... non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. ... ... (PRWEB) December 10, 2009 -- The National Eye Institute (NEI), ... a $2.18 million grant to Aciont Inc. to help fund ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3
... in the Second Quarter of 2008, SAN ... that the U.S. Food and Drug Administration,s (FDA) ... drug designation for,levofloxacin solution for inhalation for the ... other bacteria in patients,with cystic fibrosis. Levofloxacin is ...
... Set to Dramatically Improve Airway Inflammatory Disease ... Personalized Inflammation Control, NEW PROVIDENCE, N.J., March 4 ... MINO (http://www.nioxmino.com ), a,hand- held point-of-care device for ... the U.S. Food and Drug Administration (FDA).,Physicians in the ...
... Inc. (Nasdaq,CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today,reported results ... 2007 and Recent Company Highlights, -- Follow-on Biologics Program ... Stimulating Factor or ... products to enter clinical trials in 2008; ...
Other Biology Technology:Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11
(Date:12/11/2009)... species of wild apples that could be an ancestor ... and Central Asia. A new study comparing the diversity ... Georgia and Armenia with previously collected varieties originating in ... a core collection that will make M. orientalis ... , To identify and record the genetic diversity of ...
(Date:12/11/2009)... Pike, an associate professor of anthropology at the University ... northern Kenya to understand how violence shapes the health ... results of her and her colleagues, research," Documenting the ... of northern Kenya: A conceptual framework," is currently published ... Medicine , in collaboration with the British medical journal ...
(Date:12/11/2009)... ORFruit growers, profits have traditionally been limited ... where growing seasons can be short. Thanks ... varieties are being introduced that offer growers ... offseasonresulting in economic bonuses for both producers ... varieties of blackberry called "primocane-fruiting", which bear ...
Breaking Biology News(10 mins):Understanding apples' ancestors 2UA-led study grapples with health effects of low-intensity warfare 2New management methods extend blackberry season 2SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 1SEI Defined Benefit Client Recognized With Leading Plan Design Award 5454 2If You Want Help From a Chimp Youll Have to Ask 59437 1If You Want Help From a Chimp Youll Have to Ask 59437 2Are Commercial Genetic Tests Worth Taking 3F 59435 1Are Commercial Genetic Tests Worth Taking 3F 59435 2Are Commercial Genetic Tests Worth Taking 3F 59435 3
... COLLEGE STATION, Aug. 6, 2008 Think researchers know ... known as E. coli? Think again. "E. coli has ... one-fourth of these remain unknown," says Dr. Deborah Siegele, ... specializes in carrying out research using the bacterium. , ...
... NJIT and University of Sao Paulo today announced a ... safe, building block chemical derived from corn known as ... forward in developing applications and markets for corn-based chemistry. ... right to work with companies interested in sub-licensing this ...
... world in ,a different way from the rest of ... numbers or letters as ,having colors or days of ... normally in the world. Now, researchers at the ,California ... in which individuals hear sounds, such as tapping, ,beeping, ...
Other Biology News:GIANT-Coli: A novel method to quicken discovery of gene function 2Iowa Corn Promotion Board, NJIT to license breakthrough, safe bio-plastic alternative 2Caltech neurobiologists discover individuals who 'hear' movement 2Caltech neurobiologists discover individuals who 'hear' movement 3
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
... IHC Select Immunophosphatase Secondary Detection System is ... Select Prediluted Primary Antibody reagents, which contain ... identification of antigens by light microscopy in ... Detection System may also be used with ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: